Mesoblast (ASX:MSB) will issue 10.2 million ordinary shares to Osiris Therapeutics as contingent consideration in relation to the approval of its cell treatment by the US Food and Drug Administration (FDA), according to a Monday Australian bourse filing.
The FDA approved the firm's mesenchymal stromal cell therapy, Ryoncil, in December 2024, according to an earlier filing.
The shares will be subject to voluntary escrow for 12 months from the date of issue, the filing said.
Mesoblast's shares fell 6% during trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments